Oncotarget

Clinical Research Papers:

Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma

Fangzheng Wang _, Chuner Jiang, Zhimin Ye, Quanquan Sun, Tongxin Liu, Min Xu, Peng Wu, Kaiyuan Shi, Bin Long, Aizawa Rihito, Sakamoto Masoto and Zhenfu Fu

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:75544-75556. https://doi.org/10.18632/oncotarget.17357

Metrics: PDF 971 views  |   HTML 1609 views  |   ?  


Abstract

Fangzheng Wang1,2,*, Chuner Jiang3,*, Zhimin Ye1,2, Quanquan Sun1,2, Tongxin Liu1,2, Min Xu4, Peng Wu5, Kaiyuan Shi6, Bin Long7, Aizawa Rihito8, Sakamoto Masoto8 and Zhenfu Fu1,2

1 Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang Hangzhou, People’s Republic of China

2 Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Hangzhou, People’s Republic of China

3 Department of Breast Tumor Surgery, Zhejiang Cancer Hospital, Zhejiang Hangzhou, People’s Republic of China

4 Department of Physics, Zhejiang Cancer Hospital, Zhejiang Hangzhou, People’s Republic of China

5 Department of Pathology, Zhejiang Cancer Hospital, Zhejiang Hangzhou, People’s Republic of China

6 Department of Ultrasonography, Zhejiang Cancer Hospital, Zhejiang Hangzhou, People’s Republic of, China

7 Department of Nuclear Medicine, Zhejiang Cancer Hospital, Zhejiang Hangzhou, People’s Republic of China

8 Department of Radiology, Japanese Red Cross Fukui Hospital, Fukui, Japan

* These authors have contributed equally to this work

Correspondence to:

Fangzheng Wang, email:

Keywords: nasopharyngeal carcinoma, nimotuzumab, neoadjuvant chemotherapy, concurrent chemotherapy, intensity-modulated radiotherapy

Received: January 28, 2017 Accepted: April 11, 2017 Published: April 21, 2017

Abstract

We assessed the efficacy and safety of nimotuzumab plus neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for Chinese patients with locoregionally advanced nasopharyngeal carcinoma. Clinical data from 210 nonmetastatic nasopharyngeal carcinoma patients diagnosed between May 2008 and April 2014 were retrospectively reviewed. All patients were initially treated with nimotuzumab plus neoadjuvant chemotherapy followed by concurrent chemoradiotherapy. Ninety-five patients received cisplatin-based adjuvant chemotherapy. The median follow-up duration was 48 months. Locoregional relapse and distant metastases occurred in 16 patients (16/210, 7.6%) and 18 patients (18/210, 8.6%), respectively. The 5-year local recurrence-free survival, regional recurrence-free survival, distant metastases-free survival, progression-free survival, and overall survival rates were 95.6%, 94.4%, 91.7%, 84.0%, and 88.7%, respectively. Univariate analysis revealed that concurrent chemotherapy regimens and clinical stage correlated with overall survival, and that adjuvant chemotherapy, N stage, clinical stage, and tumor response at the end of treatment were correlated with progression-free survival. In the multivariate analysis, concurrent chemotherapy regimens, clinical stage, and tumor response were important prognosticators. Grade 3/4 leukocytopenia was experienced by 24 patients (11.4%), and 6 patients (2.9%) developed mild liver damage during the period of neoadjuvant chemotherapy. Grade 3/4 acute mucositis was experienced by 13 patients (6.2%), and 12 patients (5.7%) experienced grade 3/4 leukocytopenia during the concurrent chemotherapy. The efficacy of nimotuzumab plus neoadjuvant chemotherapy followed by concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma patients was encouraging and the toxicities were tolerable.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17357